Back

RedHill Biopharma acquires exclusive rights to Rebyota and Clenpiq

Verifying
  • RedHill Biopharma acquired exclusive commercialization rights to Rebyota and Clenpiq.
  • The transaction was funded through the sale of RedHill’s Talicia franchise.
  • The drugs generated $37.5 million in net s..., according to the supplied material.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.
RedHill Biopharma acquires exclusive rights to Rebyota and Clenpiq - CoinPost Terminal